Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Geron Co. stock logo
GERN
Geron
$1.65
-2.9%
$2.32
$1.46
$5.34
$1.08B0.5310.94 million shs12.11 million shs
Innoviva, Inc. stock logo
INVA
Innoviva
$17.88
+2.6%
$18.00
$14.33
$21.28
$1.12B0.56592,617 shs1.16 million shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.74
-1.7%
$1.68
$1.12
$2.04
$1.17B1.74.17 million shs2.16 million shs
Verastem, Inc. stock logo
VSTM
Verastem
$6.73
+5.2%
$6.13
$2.10
$13.52
$329.52M0.6920,711 shs815,643 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Geron Co. stock logo
GERN
Geron
0.00%0.00%-28.87%-48.48%-48.48%
Innoviva, Inc. stock logo
INVA
Innoviva
+0.23%+0.75%-3.65%-1.30%+16.29%
OPKO Health, Inc. stock logo
OPK
OPKO Health
-1.67%-4.84%+2.91%+16.45%+75.25%
Verastem, Inc. stock logo
VSTM
Verastem
-2.59%-8.31%+15.11%+62.44%-44.78%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Geron Co. stock logo
GERN
Geron
4.4624 of 5 stars
4.44.00.01.32.33.30.6
Innoviva, Inc. stock logo
INVA
Innoviva
4.4885 of 5 stars
3.51.00.04.23.62.51.9
OPKO Health, Inc. stock logo
OPK
OPKO Health
4.3422 of 5 stars
3.50.00.04.43.25.00.6
Verastem, Inc. stock logo
VSTM
Verastem
3.1037 of 5 stars
4.51.00.00.02.42.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Geron Co. stock logo
GERN
Geron
2.82
Moderate Buy$5.75248.48% Upside
Innoviva, Inc. stock logo
INVA
Innoviva
3.00
Buy$55.00207.61% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
3.00
Buy$2.7558.05% Upside
Verastem, Inc. stock logo
VSTM
Verastem
3.00
Buy$13.88106.17% Upside

Current Analyst Ratings Breakdown

Latest VSTM, OPK, GERN, and INVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/24/2025
Verastem, Inc. stock logo
VSTM
Verastem
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$13.00 ➝ $14.00
3/24/2025
Verastem, Inc. stock logo
VSTM
Verastem
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $10.00
3/21/2025
Verastem, Inc. stock logo
VSTM
Verastem
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$16.00 ➝ $14.00
3/19/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
3/12/2025
Geron Co. stock logo
GERN
Geron
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
3/12/2025
Geron Co. stock logo
GERN
Geron
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
3/12/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
3/12/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$2.25 ➝ $2.25
3/7/2025
Innoviva, Inc. stock logo
INVA
Innoviva
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$55.00
3/3/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
2/28/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$2.25 ➝ $2.25
(Data available from 3/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Geron Co. stock logo
GERN
Geron
$76.99M13.65N/AN/A$0.46 per share3.59
Innoviva, Inc. stock logo
INVA
Innoviva
$358.71M3.12$3.46 per share5.17$10.66 per share1.68
OPKO Health, Inc. stock logo
OPK
OPKO Health
$713.14M1.64N/AN/A$1.80 per share0.97
Verastem, Inc. stock logo
VSTM
Verastem
$10M34.65N/AN/A$2.27 per share2.96
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Geron Co. stock logo
GERN
Geron
-$184.13M-$0.27N/AN/AN/A-682.48%-67.53%-45.46%5/1/2025 (Estimated)
Innoviva, Inc. stock logo
INVA
Innoviva
$179.72M$0.1925.9111.54N/A18.31%20.84%11.38%5/6/2025 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$188.86M-$0.09N/AN/AN/A-18.65%-9.76%-6.46%5/6/2025 (Estimated)
Verastem, Inc. stock logo
VSTM
Verastem
-$87.37M-$3.50N/AN/AN/AN/A-332.73%-73.97%5/8/2025 (Estimated)

Latest VSTM, OPK, GERN, and INVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/20/2025Q4 2024
Verastem, Inc. stock logo
VSTM
Verastem
-$0.76-$1.33-$0.57-$1.33$0.15 millionN/A
2/27/2025Q4 2024
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.08$0.01+$0.09$0.01$155.42 million$183.60 million
2/26/2025Q4 2024
Geron Co. stock logo
GERN
Geron
-$0.04-$0.04N/A-$0.04$45.29 million$47.54 million
2/26/2025Q4 2024
Innoviva, Inc. stock logo
INVA
Innoviva
N/A$0.57N/A$0.26N/A$91.81 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Geron Co. stock logo
GERN
Geron
N/AN/AN/AN/AN/A
Innoviva, Inc. stock logo
INVA
Innoviva
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
Verastem, Inc. stock logo
VSTM
Verastem
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Geron Co. stock logo
GERN
Geron
0.04
2.89
2.74
Innoviva, Inc. stock logo
INVA
Innoviva
0.38
1.79
1.64
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.30
2.97
2.69
Verastem, Inc. stock logo
VSTM
Verastem
2.77
3.23
3.23

Institutional Ownership

CompanyInstitutional Ownership
Geron Co. stock logo
GERN
Geron
73.71%
Innoviva, Inc. stock logo
INVA
Innoviva
99.12%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%
Verastem, Inc. stock logo
VSTM
Verastem
88.37%

Insider Ownership

CompanyInsider Ownership
Geron Co. stock logo
GERN
Geron
3.10%
Innoviva, Inc. stock logo
INVA
Innoviva
1.70%
OPKO Health, Inc. stock logo
OPK
OPKO Health
47.26%
Verastem, Inc. stock logo
VSTM
Verastem
2.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Geron Co. stock logo
GERN
Geron
70636.90 million585.76 millionOptionable
Innoviva, Inc. stock logo
INVA
Innoviva
10062.68 million61.54 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
3,930671.55 million359.94 millionOptionable
Verastem, Inc. stock logo
VSTM
Verastem
5051.49 million43.53 millionOptionable

Recent News About These Companies

Verastem (NASDAQ:VSTM) Upgraded to Hold at StockNews.com
Verastem, Inc. stock logo
Verastem (NASDAQ:VSTM) Upgraded to "Hold" at StockNews.com
Verastem, Inc. stock logo
Verastem (NASDAQ:VSTM) Price Target Raised to $14.00
Verastem price target raised to $14 from $13 at Guggenheim
Verastem CFO Daniel Calkins sells shares worth $630
Verastem price target raised to $10 from $7 at H.C. Wainwright
Alliance Global Partners Remains a Buy on Verastem (VSTM)
BTIG Sticks to Its Buy Rating for Verastem (VSTM)
Verastem price target lowered to $14 from $16 at RBC Capital
Verastem reports Q4 EPS (60c), consensus (74c)
Verastem files to sell 1.42M shares of common stock for holders

New MarketBeat Followers Over Time

Media Sentiment Over Time

Geron stock logo

Geron NASDAQ:GERN

$1.65 -0.05 (-2.94%)
Closing price 04:00 PM Eastern
Extended Trading
$1.66 +0.01 (+0.30%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Innoviva stock logo

Innoviva NASDAQ:INVA

$17.88 +0.46 (+2.64%)
Closing price 04:00 PM Eastern
Extended Trading
$17.88 0.00 (0.00%)
As of 04:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.74 -0.03 (-1.69%)
Closing price 04:00 PM Eastern
Extended Trading
$1.74 0.00 (-0.29%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Verastem stock logo

Verastem NASDAQ:VSTM

$6.73 +0.33 (+5.16%)
Closing price 04:00 PM Eastern
Extended Trading
$6.76 +0.02 (+0.37%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.